# ArQule, Inc., a subsidiary of Merck trials: 32 (2026)

ClinicalTrials.gov lists 32 trials with ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) as lead sponsor, 0 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA): 32 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/arqule-inc-a-subsidiary-of-merck-sharp-and-dohme-llc-a-subsidiary-of-m

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 23, 2017 | NCT03317366 | Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Not applicable | No longer available | Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorders | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03317366) |
| May 22, 2017 | NCT03162536 | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1/2 | Active not recruiting | Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell... | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03162536) |
| March 29, 2017 | NCT03094832 | Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1/2 | Terminated | PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03094832) |
| May 5, 2016 | NCT02762721 | Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Observational | Completed | Intrahepatic Cholangiocarcinoma, Mixed Hepatocellular Cholangiocarcinoma, Cholangiocarcinoma | 131 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02762721) |
| May 4, 2016 | NCT02761694 | Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN... | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 | Terminated | Cancer, Solid Tumors | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02761694) |
| June 22, 2015 | NCT02476955 | Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 | Terminated | Solid Tumors, Ovarian Cancer, Endometrial Cancer | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02476955) |
| November 17, 2011 | NCT01473095 | Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 | Completed | Solid Tumor, Malignant Lymphoma, Tumor | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01473095) |
| July 18, 2011 | NCT01395758 | Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 2 | Completed | Metastatic Non-Small Cell Lung Cancer | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01395758) |
| October 21, 2010 | NCT01225536 | Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 | Completed | Solid Tumor | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01225536) |
| August 10, 2010 | NCT01178411 | An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1/2 | Completed | Advanced Solid Tumors | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01178411) |
| February 18, 2010 | NCT01070290 | A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer... | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 2 | Withdrawn | Gastric Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01070290) |
| October 2, 2009 | NCT00988741 | Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 2 | Completed | Unresectable Hepatocellular Carcinoma | 107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00988741) |
| April 2, 2009 | NCT00874042 | Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 | Completed | Advanced Solid Tumors | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00874042) |
| January 22, 2009 | NCT00827177 | Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 | Completed | Advanced Solid Tumors | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00827177) |
| January 21, 2009 | NCT00825487 | Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 | Completed | Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00825487) |
| December 5, 2008 | NCT00802555 | Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 | Completed | Cirrhosis, Hepatocellular Carcinoma | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00802555) |
| October 22, 2008 | NCT00777309 | A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or... | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 2 | Completed | Non Small Cell Lung Cancer | 167 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00777309) |
| April 15, 2008 | NCT00658554 | Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00658554) |
| April 3, 2008 | NCT00651638 | A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by... | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 | Completed | Healthy | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00651638) |
| February 22, 2008 | NCT00622063 | An Extension Study for Patients Previously Treated With ARQ 501 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1/2 | Completed | Cancer | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00622063) |
| February 12, 2008 | NCT00612703 | A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 | Completed | Cancer | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00612703) |
| February 11, 2008 | NCT00612209 | A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 | Completed | Cancer, Advanced Solid Tumors | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00612209) |
| November 14, 2007 | NCT00558207 | A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic... | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 2 | Completed | Pancreatic Neoplasms | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00558207) |
| November 14, 2007 | NCT00557609 | Phase 2 Study in Patients With MiT Tumors | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 2 | Completed | Renal Cell Carcinoma (RCC), Alveolar Soft Part Sarcoma (ASPS), Clear Cell Sarcoma (CCS) | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00557609) |
| September 3, 2007 | NCT00524524 | An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 | Completed | Advanced Solid Tumors | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00524524) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 17 |
| Phase 1/2 | 4 |
| Phase 2 | 9 |
| Not applicable | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 25 |
| Terminated | 4 |
| Withdrawn | 1 |
| Active not recruiting | 1 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 16 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Carcinoma, Hepatocellular | 3 |
| Lymphoma | 3 |
| Carcinoma, Renal Cell | 3 |
| Pancreatic Neoplasms | 2 |
| Ovarian Neoplasms | 2 |
| Endometrial Neoplasms | 2 |
| Carcinoma | 2 |
| Neoplasm Metastasis | 2 |
| Hereditary Sensory and Autonomic Neuropathies | 2 |
| Congenital Abnormalities | 2 |
| Melanoma | 2 |
| Breast Neoplasms | 2 |
| Hematologic Neoplasms | 2 |
| Neoplasms, Plasma Cell | 2 |
| Leukemia | 2 |
| Stomach Neoplasms | 1 |
| Uterine Cervical Neoplasms | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Cholangiocarcinoma | 1 |
| Liver Neoplasms | 1 |
| Adenocarcinoma | 1 |
| Fibrosis | 1 |
| Sarcoma, Alveolar Soft Part | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Podiatrists in the United States](https://specstream.ai/data/businesses/podiatrists/united-states)
- [Hotel bars in the United States](https://specstream.ai/data/businesses/hotel-bars/united-states)
- [Colombian restaurants in the United States](https://specstream.ai/data/businesses/colombian-restaurants/united-states)
- [Welding supply stores in the United States](https://specstream.ai/data/businesses/welding-supply-stores/united-states)
- [Polynesian restaurants in the United States](https://specstream.ai/data/businesses/polynesian-restaurants/united-states)
- [Housing or property companies in the United States](https://specstream.ai/data/businesses/housing-or-property-companies/united-states)
